B+
Bull case
30%
Probability
Target price
$360.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
LH
LabcorpBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$338.40
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$275.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-04
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+71.8
Score
AI commentary
News tone is strongly positive after the earnings beat and guidance increase. LH rose 2.73% on July 30, then gave back part of the move over the following sessions; subsequent analyst target increases were constructive. [Price history](https://stockanalysis.com/stocks/lh/history/) Social, options, short-interest, and employee-sentiment data are unavailable, so confidence should remain below a full-conviction bullish rating.
RankAlpha Sentiment Codex - 2026-08-04
Open post-earnings memoEvidence flagged
high-coverage report lacks a dated company-specific catalyst beyond generic cadence; peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-07-30eventQ2 beat and raised FY2026 outlookMedium impact
Q2 revenue was $3.73 billion, adjusted EPS was $4.99, and Labcorp raised revenue-growth midpoint guidance by 30 basis points and adjusted EPS midpoint guidance by $0.30; the remaining repurchase authorization rose to $1.4 billion. [#SEC-8K-2026-07-30] [SEC 8-K](https://www.sec.gov/Archives/edgar/data/920148/000092014826000162/form8-kexhibit9912q26.htm)
2026-08-08catalystPost-print analyst target revisionsMedium impact
Several analysts raised price targets after the print, including JPMorgan to $360 from $330 and Piper Sandler to $309 from $300, while maintaining their respective ratings. [Analyst revision coverage](https://www.tipranks.com/news/the-fly/labcorp-price-target-raised-to-360-from-330-at-jpmorgan-thefly-news)
2027-08-04catalystNASHnext Medicare coverage checkpointHigh impact
Stored earnings-call context says Labcorp's NASHnext blood-based liver-disease test is scheduled to receive Medicare coverage beginning in mid-August, creating a dated reimbursement and commercialization checkpoint alongside continued specialty-testing rollout. [#PR-EARNINGS-2026-07-31]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-04 • Updated nightlySource: Internal modelMethodology